News Sofinnova closes new fund and backs a trio of new biotechs Sofinnova Partners has raised €165m for its new biotech fund and backed three startups working on Alzheimer's, fibrotic diseases, and cell therapies.
Oncology A quarter of cancer patients don’t respond to targeted thera... The more progress we make in precision medicine, the more edge cases we discover.
News Sofinnova raises €1.2bn to back 'up to 60' companies Sofinnova has raised €1.2bn that it says could support 50 to 60 companies across biotech, medtech, industrial biotech, and digital medicine.
News Perlmutter's Eikon raises $351m in major financing round Eikon has added to its already copious cash reserves with a $351m round for its expanding pipeline of cancer therapies.
News Two more biotechs, Metsera and Maze, cross IPO finish line Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.
News Ascentage raises $126m in first biotech IPO of 2025 China's Ascentage completes the first US biotech IPO of 2025, raising $126m for its pipeline of small-molecule cancer drugs.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl